Good MorningThe S&P 500 pulled back on Wednesday due to an increasingly tepid outlook put forth by the retail sector. The latest report to weigh on the market comes from Target which missed estimates on the top and bottom lines, the bottom line by a very wide margin. The report highlights a growing problem in the retail sector in the form of bloating inventories that spells bad news for earnings and good news for consumers. With inventories at unusually high levels, retailers may be forced to follow in Target's footsteps and enter a new age of deep discounting to move merchandise.
The decline in stocks was curbed, however, by the FOMC minutes. The minutes indicate the Fed is ready to hike rates until inflation comes down substantially from its current high levels but gave no indication of the pace or timing of hikes. The market is pricing in a 50 basis point hike at the next meeting but there are still several inflation reports due out before then. Featured: The 7 Stocks Quietly Gaining Attention Right Now (Ad) 
|
Technology | | ON Semiconductor (NASDAQ: ON) has taken a leadership role within its industry lately, as the stock notched gains of 26.11% in the past month and 28.21% in the past three months.
Other large-cap chip companies, such as Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD) have shown fundam... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Materials | | Metal miner Rio Tinto (NYSE: RIO) is up 7.8% since reporting first-half earnings in late July. Earnings declined 29%, to $2.73 per share, while revenue dropped 10% to $14.9 billion.
Although that was actually an earnings beat, the company also slashed its dividend in response to lower iron ore pri... Read the Full Story |
|
Industrials | |
If you've ever had an interest in business aviation, combat vehicles, weapons systems and munitions or shipbuilding and ship repair, General Dynamics Corporation (NYSE: GD) might be right up your alley.
General Dynamics pays an annual dividend of $5.04 per share and has a dividend yield of 2.1%.... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Healthcare | |
Agilent Technologies (NYSE: A) is a highly-valued stock for the low 0.6% dividend that it pays but the Q2 results once again prove the company’s worth. The results include a top and bottom line beat as well as improved guidance that has the shares moving higher in their wake. With competitor... Read the Full Story |
|
Consumer Discretionary | |
Lowe’s (NYSE: LOW) Q2 results may look weaker than Home Depot’s (NYSE: HD) at first glance but there is a meaningful difference in the guidance. Where Home Depot’s outlook was improved it is only in line with the consensus and projects a weakening in the 2nd half, Lowe’s wa... Read the Full Story |
|
From Our Partners | | Amazing backtest. Beautiful sales pitch. Then real money goes in and things look very different. Sound familiar?
Former Wells Fargo Senior Financial Advisor Brian Jackson is hosting a free Investor Briefing on what he looks for before trusting an automated strategy with capital, including how Vincere's futures algorithms approach risk.
See how it actually works before deciding for yourself. | | Reserve your free seat to see behind the curtain now |
|
Consumer Staples | |
Target’s (NYSE: TGT) Q2 results reinforce a problem facing the retail sector that was only hinted at by Walmart (NYSE: WMT) and Home Depot (NYSE: HD) earlier in the week. The company’s efforts to combat supply chain and inventory hurdles are catching up with it at the same time that de... Read the Full Story |
|
Markets | | Activision Blizzard (NASDAQ: ATVI) stock hasn’t gotten much traction since its earnings report on August 1.
On the one hand, that lack of movement is not particularly surprising, given that Microsoft has offered to buy the game software and console maker for $68.7 billion, or $95 per share. ... Read the Full Story |
|
Consumer Staples | |
Coca-Cola (NYSE:KO) and PepsiCo (NASDAQ:PEP) are part of the consumer staples sector. This sector includes many of the leading defensive stocks. A feature of the best companies in this sector is that they offer products that consumers will buy no matter what is happening in the broader economy.
... Read the Full Story |
|
Industrials | |
Mr. President, investors were banking on you signing that enormous climate, health, and tax bill.
With the President signing off on the landmark $430 billion package that earmarks a sizable chunk to clean energy policies, electric vehicle (EV) stocks have been, well, electric as of late.
Since t... Read the Full Story |
|
Technology | |
Shares of Apple (NASDAQ: AAPL) are approaching their 52-week high and many analysts believe AAPL stock could cross over $200 per share by the end of the year. If it does so, it won’t be exclusively due to iPhone sales (although those sales still are strong).
As many shareholders know, App... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. | | View Today's Stock Pick |
|
